Global blood therapeutics, inc. (GBT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-73,026

-95,975

-64,547

-57,321

-48,923

-49,202

-43,067

-40,368

-41,556

-41,252

-28,557

-23,883

-23,332

-27,207

-20,986

-17,675

-16,600

-15,585

-14,764

-8,594

-7,417

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,238

2,311

2,107

2,093

2,094

2,098

1,167

672

670

650

400

275

333

319

321

278

242

267

217

206

183

Amortization (accretion) of premium (discount) on marketable securities

101

333

520

639

565

435

333

-14

-93

-143

-181

-196

-184

-

-

-

-

-

-

-

-

Non-cash interest expense

412

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

693

995

120

112

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

16,367

12,797

12,453

10,948

9,453

7,528

6,968

7,800

7,784

4,741

3,707

2,660

2,574

3,351

3,152

1,465

1,267

1,492

874

535

322

Loss from disposal of fixed assets, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

0

-11

-18

Changes in operating assets and liabilities:
Accounts receivables

1,941

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

13,218

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

147

-2,132

5,276

-10

-49

-1,996

2,077

1,742

677

-1,017

323

1,202

1,348

277

57

-261

688

-402

1,205

-338

-378

Other assets, current

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-232

153

-305

362

Accounts payable

2,567

3,411

530

-714

1,272

846

1,586

-3,979

262

3,710

-1,562

1,886

-1,263

2,544

-2,667

322

867

1,854

156

361

334

Payable due to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39

Accrued liabilities

-6,766

19,149

-579

5,249

887

2,149

3,988

1,769

125

2,380

-475

-1,107

2,482

48

950

-18

814

906

877

297

754

Accrued compensation

-6,309

7,128

2,210

2,612

-4,407

2,857

939

1,517

-3,856

3,058

1,029

1,717

-2,192

1,616

495

1,141

-527

794

666

240

-305

Operating lease liabilities

1,762

1,751

-295

-287

-276

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-1,153

-

-

-

0

-919

-73

183

389

421

-12

-20

-13

-35

-13

-3

-9

-18

0

-2

-5

Net cash used in operating activities

-78,622

-62,337

-53,827

-37,937

-40,316

-33,573

-30,902

-34,134

-36,766

-25,357

-25,612

-19,478

-22,575

-20,052

-18,808

-14,229

-14,634

-9,647

-8,840

-6,342

-6,061

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment

2,524

2,262

650

492

56

-122

1,646

2,798

502

1,328

1,198

401

174

246

151

577

378

218

220

386

169

Purchase of marketable securities

57,936

104,789

134,833

31,120

164,177

-

-

-

-

3

2,860

46,120

78,741

-

-

-

-

-

-

-

-

Maturities of marketable securities

151,586

127,636

112,914

57,341

63,582

73,290

31,929

34,702

42,076

43,891

19,324

23,498

9,287

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

91,126

20,630

-22,569

25,729

-100,651

-28,287

-116,790

-80,654

41,574

42,385

15,266

-23,023

-69,628

-105,746

-151

-577

-378

-218

-220

-386

-169

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in public offering, net

-

0

5,454

192,782

21,207

141,382

0

179

254,940

96,330

0

-80

135,705

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

521

67

Proceeds from sale of restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,063

45

Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options

2,968

7,967

1,624

2,341

1,925

947

2,826

1,075

2,821

826

1,412

578

1,076

123

619

4

494

1

33

11

0

Payments of debt issuance costs

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of unvested restricted stock purchases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-1

50

17

Tax paid related to net share settlement of equity awards

2,099

4,102

1,532

1,297

686

-1

849

0

5,404

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

784

76,340

5,546

193,826

22,446

142,326

1,969

1,254

252,357

97,155

754

498

136,781

33

4,886

112,732

494

-130

126,982

1,503

-39

Net increase (decrease) in cash, cash equivalents and restricted cash

13,288

34,633

-70,850

181,618

-118,521

80,466

-145,723

-113,534

257,165

114,183

-9,592

-42,003

44,578

-125,765

-14,073

97,926

-14,518

-9,995

117,922

-5,225

-6,269

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Leasehold improvements paid for by landlord

9,461

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series A redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

787

2,153

1,240

Accrued purchase of property and equipment

563

2

-71

1

146

2,221

-772

-2,488

1,087

1,438

68

-80

110

-133

234

-30

43

-

-

-330

356

Accrued issuance costs

-85

-

-

487

-41

-

-

-

127

-

-

-

88

-

-

-

-

-

-244

-246

620